Profit: A$215m, down 21% though underlying ebitda was up 7.5% to A$585m.
Key takeaway: Market disappointed by FY26 guidance in range of A$615m to A$635m, well below consensus forecasts.
Shareholders have punished a disappointing FY25 result from dual-listed healthcare and animal care company Ebos Group today, with its share price dropping 12% on the NZX and 15% on the ASX in today’s trading.
The group reported revenue down 7% to A$12.3 billion for the year ending June 30, 2025,
